Psoriasis
📧 Sign up to get email alerts when something new happens for Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2014-11-21Clinical Trial Update: The Effectiveness of Lower Cyclosporine Doses for Psoriasis [Phase 2]
A Phase 2 trial evaluating lower doses of cyclosporine for psoriasis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-11-10Clinical Trial Update: Erlotinib for Treatment of Psoriasis [Phase 2]
A Phase 2 trial of Tarceva (erlotinib) for psoriasis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-12-16Clinical Trial Update: The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients [NA]
A clinical trial evaluating the effect of weight loss on the Psoriasis Area Severity Index in adults with psoriasis was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-11-18Clinical Trial Update: Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis
This document reports the withdrawal of a post-marketing surveillance trial evaluating the safety and efficacy of Enbrel (etanercept) in ped…
-
CLINICAL_TRIALS withdrawal · 2013-08-15Clinical Trial Update: Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo. [Phase 3]
A Phase 3 trial evaluating subcutaneous secukinumab for chronic plaque psoriasis, comparing it with etanercept and placebo, has been withdra…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2013-01-24Clinical Trial Update: The Effect of Algae Dunaliella Bardawil on Psoriasis (2) [Phase 3]
A Phase 3 trial evaluating Dunaliella bardawil algae extract for psoriasis was withdrawn, with no results reported.
-
EMA withdrawal · 2011-01-31EMA Application withdrawn: Ozespa (briakinumab) — Abbott Laboratories Ltd.
The EMA withdrew the application for Ozespa (briakinumab) by Abbott Laboratories Ltd. for psoriasis.
-
EMA withdrawal · 2009-08-04EMA Withdrawn: Raptiva (efalizumab) — Serono Europe Limited
Raptiva (efalizumab) has been withdrawn from the market in Europe by Serono Europe Limited for psoriasis.